{
    "key_points": [
        "FDA advisory panel votes in favor of authorizing Pfizer's COVID-19 vaccine for children ages 5 to 11.",
        "17 out of 18 committee members voted in favor, with one abstention.",
        "Final authorization depends on further FDA decision and CDC recommendations.",
        "Panel members acknowledged concerns over rare side effects but highlighted the vaccine's benefits.",
        "Data shows over 1.9 million COVID-19 infections and close to 100 deaths in the 5 to 11 age group.",
        "Pfizer's clinical trials suggest the vaccine is over 90% effective in preventing symptomatic disease in children.",
        "Concerns discussed about myocarditis and pericarditis, rare side effects seen in younger vaccine recipients.",
        "Approximately 877 cases of myocarditis or pericarditis reported in Americans under 30 with over 400 million doses administered.",
        "FDA's models suggest vaccine benefits outweigh risks, depending on COVID-19 case incidence.",
        "Pfizer's pediatric vaccine doses could begin distribution early November, pending final approvals."
    ],
    "spokespersons": [
        "Dr. Mark Sawyer (Member, FDA's Vaccines and Related Biological Products Advisory Committee)",
        "Dr. Michael Nelson (Member, Vaccine and Related Biological Products Advisory Committee)",
        "Dr. Peter Marks (Top Vaccines Official, FDA)",
        "Dr. William Gruber (Senior Vice President of Vaccine Clinical Research and Development, Pfizer)"
    ],
    "article_type": "general reporting",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}